

Contents

Chapter 1

Anthrax: A Disease and a Weapon

Kenneth Alibek, Catherine Lobanova, and Serguei Popov

1. History of Anthrax	1
1.1. Anthrax in the United States	3
2. Anthrax as a Biological Weapon	4
3. The Organism	8
4. Pathogenesis of Anthrax Infection	10
5. Clinical Manifestation of Anthrax Infection	13
5.1. Cutaneous Anthrax	14
5.2. Systemic Anthrax	14
5.2.1. General Symptoms of Anthrax Infection	15
5.2.2. Respiratory Symptoms and Findings	17
5.2.3. Neurological Symptoms and Signs	18
5.2.4. Cardiovascular Symptoms and Signs	19
5.2.5. Gastrointestinal Symptoms and Signs	19
5.2.6. Miscellaneous	20
5.2.7. Findings—Autopsies	21
6. Considerations on Clinical Manifestations of Systemic Anthrax	23
7. Laboratory Diagnosis	24
8. Vaccination	24
9. Postexposure Prophylaxis	25
10. Treatment of Anthrax Infection	25
11. Protection	28
12. Isolation	29
13. Afterward	29
Acknowledgments	29
References	29

Chapter 2

Plague as a Biological Weapon

David T. Dennis

1. History of Plague and Its Potential as a Weapon of Bioterrorism	37
1.1. Pandemic History and Epidemic Potential	37
1.2. Plague as a Weapon of Biological Warfare	38
1.3. US Countermeasures to Plague as a Weapon of Terrorism	39
1.4. Preparedness and Response to a Possible Plague Attack	40
2. Plague Microbiology and Pathogenesis	41
2.1. The Agent	41
2.1.1. General Characteristics	41
2.1.2. Molecular Genetics	42
2.2. Pathogenicity of <i>Y. pestis</i>	42
2.2.1. Virulence Factors	42
2.2.2. Pathology of Infection	43
3. Clinical Spectrum	44
3.1. Bubonic Plague	44
3.2. Septicemic Plague	46
3.3. Pneumonic Plague	48
3.4. Other Clinical Syndromes	50
3.5. Pediatric Plague	50
3.6. Plague in Pregnancy	51
4. Diagnosis	51
4.1. Laboratory Diagnosis	51
4.1.1. Laboratory Response Capabilities	51
4.1.2. Collection and Processing of Specimens	52
4.2. Recognizing a Plague Outbreak Resulting from Intentional Release	53
4.3. Detection of <i>Y. pestis</i> in the Environment	53
5. Medical Management of Plague Patients	55
5.1. Antimicrobial Treatment of Acute Illness in Naturally Occurring Plague	55
5.2. Postexposure Prophylaxis	57
5.3. Treatment of Cases and Case Contacts in a Bioterrorism Event	58
6. Infection Control	60
6.1. Hospital Infection Control	60
6.2. The Role of Isolation and Quarantine	61
7. Prevention	62
7.1. Prevention and Control of Naturally Occurring Plague	62
7.1.1. General Guidelines	62
7.2. Plague Vaccine	63
8. Research Directions	63
References	64

Chapter 3

Tularemia and Bioterrorism

Lisa Hodges and Robert L. Penn

1. Introduction	71
2. Microbiology	72
2.1. Taxonomy	72
2.2. Virulence	73
3. Pathogenesis	74
3.1. Pathophysiology	74
3.2. Host Immunity	75
3.2.1. Humoral Immunity	75
3.2.2. Cellular Immunity	76
3.2.3. Immune Responses in the Lungs	77
4. Epidemiology	78
5. Clinical Manifestations	80
5.1. Nonpneumonic Tularemia	80
5.2. Pneumonic Tularemia	82
5.3. Spectrum of Disease following Intentional Release of <i>F. tularensis</i>	83
5.4. Complications	84
6. Diagnosis	84
7. Treatment	86
7.1. Treatment of Endemic Tularemia	86
7.2. Treatment of Tularemia Resulting from Bioterrorism	88
8. Infection Control	89
9. Prevention	90
9.1. Antibiotic Prophylaxis	90
9.2. Vaccination	91
10. Future Directions	92
References	92

Chapter 4

Melioidosis and Glanders as Possible Biological Weapons

David Allan Brett Dance

1. Introduction	99
2. History, Distribution, and Epidemiology	99
2.1. Melioidosis	99
2.2. Glanders	101
3. Microbiology and Pathogenesis	101
3.1. Taxonomy	101
3.2. Characteristics	102
3.2.1. General	102
3.2.2. Antigenic Structure	102
3.3. Ecology and Environmental Survival	104

3.4. Antibiotic Susceptibility	104
3.5. Genomics	105
3.6. Typing Systems	106
3.7. Bacterial Virulence	106
3.7.1. Endotoxin and Lipids	106
3.7.2. Capsule	107
3.7.3. Flagella	107
3.7.4. Exotoxins and Enzymes	107
3.7.5. Secretion Systems	108
3.7.6. Siderophores	108
3.7.7. Adhesion	108
3.7.8. Intracellular Growth	109
3.8. Host Defense	110
3.8.1. Humoral Immunity	111
3.8.2. Intrinsic and Cellular Immunity	111
3.8.3. Immunopathogenesis	112
4. Clinical Spectrum	112
4.1. Melioidosis	112
4.1.1. Mild and Subclinical Infections	113
4.1.2. Latent Infections	113
4.1.3. Clinical Disease	113
4.2. Glanders	115
5. Animal Models	116
5.1. Melioidosis	116
5.2. Glanders	117
6. Potential as a Biological Weapon	117
6.1. Glanders	117
6.2. Melioidosis	118
7. Diagnosis and Treatment	119
7.1. Clinical Diagnosis	119
7.2. Laboratory Diagnosis	120
7.2.1. Microscopy and Culture	120
7.2.2. Serological Methods	122
7.2.3. Molecular Diagnosis	123
7.3. Treatment	124
7.3.1. General	124
7.3.2. Specific Chemotherapy	124
7.3.3. Adjunctive Treatments	126
7.3.4. Outcome and Follow-up	126
8. Infection Control Measures	126
8.1. Secondary Spread and Isolation	126
8.2. Environmental Contamination	127
8.3. Antibiotic Prophylaxis and Vaccines	127
9. Future Direction	128
References	129

Chapter 5

Smallpox as a Weapon for Bioterrorism

J. Michael Lane

1. Introduction	147
2. Virology	147
3. Pathogenesis	148
4. Clinical Disease	149
5. Diagnosis	151
6. Epidemiology	153
6.1. Surveillance and Containment Strategy	153
7. Patient Management and Infection Control	154
8. Potential as a Bioweapon	155
9. Prevention	158
9.1 Vaccination Policy	159
10. Future Directions	161
References	162

Chapter 6

Hemorrhagic Fever Viruses as Biological Weapons

Allison Groseth, Steven Jones, Harvey Artsob, and Heinz Feldmann

1. Introduction	169
2. Epidemiology	173
2.1. <i>Filoviridae</i> : Ebola and Marburg viruses	175
2.2. <i>Arenaviridae</i> : Lassa Fever, Junin, Machupo, Guanarito, and Sabia	177
2.3. <i>Bunyaviridae</i> : Rift Valley Fever and Crimean-Congo Hemorrhagic Fever	179
3. Patient Management	180
3.1. Clinical Recognition	180
3.2. Laboratory Diagnosis	180
3.3. Treatment	181
4. Vaccines	183
5. Public Health Measures	184
5.1. Infection Control	184
5.2. Environmental Decontamination	185
6. Ongoing Research and Proposed Agenda	186
7. Conclusions	186
Acknowledgments	187
References	187

Chapter 7

Botulism as a Potential Agent of Bioterrorism

Thomas P. Bleck, MD, FCCM

1. Introduction	193
2. History of Botulism	194
3. Botulinum Toxin as a Weapon	195
4. Diagnosis	198
5. Treatment	200
6. Management	201
References	202

Chapter 8

Ricin: A Possible, Noninfectious Biological Weapon

Maor Maman, MD, and Yoav Yehezkelli, MD

1. Introduction	205
2. History	205
2.1. The Story of a “Death Umbrella”	206
3. The Toxin	208
3.1. Toxicity	209
4. Ricin as a Potential Bioweapon	210
5. Clinical Presentation	211
5.1. Prognosis	212
5.2. Diagnosis	212
6. Treatment	212
7. Prevention and Vaccine	213
8. Medical Use of Ricin	214
9. Conclusion	214
Acknowledgments	214
References	215

Chapter 9

Bioterrorism Alert for Health Care Workers

*Theodore J. Cieslak, MD, George W. Christopher, MD,
and Edward M. Eitzen, Jr., MD, MPH*

1. Introduction	217
2. Step 1. Maintain a Healthy “Index of Suspicion” (Or, “How to Recognize Illness Due to Biological Weapons”)	218
3. Step 2. Protect Thyself First	219
3.1. Physical Protection	220
3.2. Chemical Protection	220
3.3. Immunologic Protection (Including “Pros and Cons of Mass Vaccination”)	221

4. Step 3. Save the Patient’s Life (“The Primary Assessment”) 224

5. Step 4. Disinfect or Decontaminate as Appropriate 224

6. Step 5. Establish a Diagnosis (“The Secondary Assessment”) 226

7. Step 6. Provide Prompt Therapy 226

8. Step 7. Institute Proper Infection Control Measures 228

9. Step 8. Alert the Proper Authorities (“Which Agency Should One
Notify for Suspicious Cases?”) 229

10. Step 9. Conduct an Epidemiologic Investigation (and Manage
the Medical and Psychological Aftermath of a Bioterror Attack) 232

11. Step 10. Maintain a Level of Proficiency 233

Acknowledgments 234

References 234

Chapter 10

The Economics of Planning and Preparing for Bioterrorism

Martin I. Meltzer

1. Introduction 237

2. How Many Resources?: Basic Concept 237

3. Refining the Basic Concept: Being More Realistic 238

3.1. Cost of Deploying a Planned Intervention 239

3.2. A Special Case: Optimal Amount for Pre-event
Protective Interventions 239

3.3. Example 1: Annual “Premiums” for Pandemic
Influenza Preparations 241

3.4. Example 2: Annual “Premiums” to Reduce Probability
of Losses Due to Anthrax Attack 242

4. Categories of Interventions 244

4.1. Postevent Medical Interventions (Reaction Interventions) 246

4.2. Pre-event Medical Interventions (Reaction Interventions) 246

4.3. Pre-event Protective Interventions: Reducing the
Probability of Attack 247

4.4. Calculating the Savings in Post-event Interventions
Due to Pre-event Interventions 247

5. Selecting Interventions for Evaluation for Funding 248

6. Calculating the Number of Casualties and Casualties Averted 249

6.1. Types of Mathematical Models 249

6.1.1. Increasing Complexity 250

6.1.2. Deterministic Mathematical Models 250

6.1.3. Stochastic Models 251

6.2. Model Limitations 251

6.2.1. Size of Attack 251

6.2.2. Numbers Initially Infected and Implicit Assumptions 252

6.2.3. Why Not Use “Worst Case?” 252

6.3. Realistic Expectations and Keeping It Simple 253

6.3.1. Sensitivity Analyses and Policy Levers 253

7. Calculating the Value of Casualties and Other Losses Averted	254
8. Probability of an Event Occurring	255
9. Selecting Between the Options	256
10. Summary	256
References	257